Send us Fan Mail This week on Just MS News, we look at four developments in multiple sclerosis research and diagnosis — including an important FDA regulatory milestone for CAR-T therapy in progressive MS. This week: 🔶 CAR-T for non-active SPMS The FDA has granted RMAT designation to miv-cel, an experimental CD19 CAR-T therapy being studied in non-active secondary progressive MS. The designation could help accelerate its development — but it is not FDA approval, and the human evidence remains very early. 🔶 New 2024 McDonald Criteria Updated MS diagnostic criteria may allow more people to meet diagnostic criteria earlier. One major change is the inclusion of the optic nerve as a fifth location when evaluating dissemination in space. 🔶 Lucid-MS moves toward Phase 2 Lucid-MS has been cleared to begin Phase 2 testing in progressive MS. The experimental therapy takes a different approach by targeting biological processes associated with myelin damage. Human evidence of benefit in MS has not yet been established. 🔶 Artificial Axons and remyelination research Researchers are developing engineered artificial-axon models that may provide a better way to test potential remyelination drugs before they move toward human trials. This is a drug-discovery platform — not an MS treatment. Related research: Last week, Just MS News covered lab-grown “mini-brains” being used to study myelin repair. This week’s Artificial Axons story tackles a similar problem from a different direction — using engineered nerve-fibre models to test how oligodendrocytes form myelin and how candidate remyelination drugs behave. Together, they highlight a broader challenge in MS research: building better laboratory models before potential treatments move into human trials. Sources: CAR-T / miv-celTitle: Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial ResultsAuthor/Source: Kyverna Therapeutics Published: August 11, 2026 Live link: https://ir.kyvernatx.com/news-releases/ This is the company release announcing that FDA granted RMAT designation to miv-cel for non-active SPMS. 2024 McDonald Criteria / Earlier MS DiagnosisTitle: Applying the 2024-revised McDonald criteria for multiple sclerosis using conventional diagnostic tools: a single-centre prospective cohort study in GermanyLead author: F. F. Konen Journal: eClinicalMedicine DOI: 10.1016/j.eclinm.2026.104098 Live link: https://www.sciencedirect.com/science/article/pii/S2589537026003512 This is the 215-person study behind the 93.5% vs 84%, optic-nerve 55%, and VEP 89% figures. Lucid-MS / Phase 2Title: FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple SclerosisAuthor: Marco Meglio Outlet: NeurologyLive Published: August 13, 2026 Live link: https://www.neurologylive.com/view/fda-clears-phase-2-trial-demyelinating-agent-lucid-ms-progressive-multiple-sclerosis The article covers the FDA-cleared IND, Phase 1 healthy-volunteer results, PAD2 mechanism, and planned randomized Phase 2 trial. Artificial Axons / Remyelination Drug ScreeningTitle: MIT spinout Artificial Axon gets NINDS backing for MS lesion-mimicking drug screening platformSource: AllSci Published: August 11, 2026 Live link: https://allsci.com/news/grants/ms-drug-screening-platform-artificial-axon-labs/ This is the source reporting the $1.48 million NINDS SBIR Phase II funding. For the Artificial Axon science itself, the underlying 2025 paper is also worth linking: Myelin ensheathment and drug responses of oligodendrocytes are modulated by stiffness of artificial axons Mingyu Yang, Calliope J. L. Martin, Kavin Kowsari, Anna Jagielska, Krystyn J. Van Vliet PLOS ONE, 2025 The goal of Just MS News is simple: explain what happened, what the evidence actually shows, and why it matters for people living with MS. Subscribe for weekly MS research, treatment and community news. The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com